Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947247246> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2947247246 abstract "Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%. However, little is known about the value of adding chemotherapy to pembrolizumab in this setting. Therefore, we performed an indirect comparison for pembrolizumab plus chemotherapy versus pembrolizumab, using the frequentist methods. The primary outcomes were overall survival (OS), progression-free survival (PFS) and objective response rate (ORR). Data were retrieved from randomized trials comparing pembrolizumab plus chemotherapy or pembrolizumab monotherapy against chemotherapy. Five trials involving 1289 patients were included. Direct meta-analysis showed that both pembrolizumab plus chemotherapy (ORR: relative risk (RR) 2.16; PFS: hazard ratio (HR) 0.36; OS: HR 0.51) and pembrolizumab alone (ORR: RR 1.33; PFS: HR, 0.65; OS: HR 0.67) improved clinical outcomes compared with chemotherapy. Indirect comparison showed that pembrolizumab plus chemotherapy was superior to pembrolizumab alone, in terms of ORR (RR 1.62, 1.18–2.23) and PFS (HR 0.55, 0.32–0.97). A trend towards improved OS was also observed (HR 0.76, 0.51–1.14). In conclusion, the addition of chemotherapy to pembrolizumab further improves the outcomes of patients with advanced NSCLC and a PD-L1 TPS of at least 50%." @default.
- W2947247246 created "2019-06-07" @default.
- W2947247246 creator A5003608372 @default.
- W2947247246 creator A5053008395 @default.
- W2947247246 creator A5060162680 @default.
- W2947247246 creator A5063253432 @default.
- W2947247246 creator A5066716873 @default.
- W2947247246 creator A5070121957 @default.
- W2947247246 creator A5082169968 @default.
- W2947247246 date "2019-05-03" @default.
- W2947247246 modified "2023-10-12" @default.
- W2947247246 title "First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy" @default.
- W2947247246 cites W2005947177 @default.
- W2947247246 cites W2504323515 @default.
- W2947247246 cites W2527905628 @default.
- W2947247246 cites W2529904548 @default.
- W2947247246 cites W2606328036 @default.
- W2947247246 cites W2796582438 @default.
- W2947247246 cites W2806388842 @default.
- W2947247246 cites W2892640821 @default.
- W2947247246 cites W2898458190 @default.
- W2947247246 cites W2906250995 @default.
- W2947247246 doi "https://doi.org/10.1186/s40425-019-0600-6" @default.
- W2947247246 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6500047" @default.
- W2947247246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31053172" @default.
- W2947247246 hasPublicationYear "2019" @default.
- W2947247246 type Work @default.
- W2947247246 sameAs 2947247246 @default.
- W2947247246 citedByCount "55" @default.
- W2947247246 countsByYear W29472472462019 @default.
- W2947247246 countsByYear W29472472462020 @default.
- W2947247246 countsByYear W29472472462021 @default.
- W2947247246 countsByYear W29472472462022 @default.
- W2947247246 countsByYear W29472472462023 @default.
- W2947247246 crossrefType "journal-article" @default.
- W2947247246 hasAuthorship W2947247246A5003608372 @default.
- W2947247246 hasAuthorship W2947247246A5053008395 @default.
- W2947247246 hasAuthorship W2947247246A5060162680 @default.
- W2947247246 hasAuthorship W2947247246A5063253432 @default.
- W2947247246 hasAuthorship W2947247246A5066716873 @default.
- W2947247246 hasAuthorship W2947247246A5070121957 @default.
- W2947247246 hasAuthorship W2947247246A5082169968 @default.
- W2947247246 hasBestOaLocation W29472472461 @default.
- W2947247246 hasConcept C121608353 @default.
- W2947247246 hasConcept C126322002 @default.
- W2947247246 hasConcept C143998085 @default.
- W2947247246 hasConcept C207103383 @default.
- W2947247246 hasConcept C2776256026 @default.
- W2947247246 hasConcept C2776694085 @default.
- W2947247246 hasConcept C2777701055 @default.
- W2947247246 hasConcept C2780057760 @default.
- W2947247246 hasConcept C44249647 @default.
- W2947247246 hasConcept C71924100 @default.
- W2947247246 hasConceptScore W2947247246C121608353 @default.
- W2947247246 hasConceptScore W2947247246C126322002 @default.
- W2947247246 hasConceptScore W2947247246C143998085 @default.
- W2947247246 hasConceptScore W2947247246C207103383 @default.
- W2947247246 hasConceptScore W2947247246C2776256026 @default.
- W2947247246 hasConceptScore W2947247246C2776694085 @default.
- W2947247246 hasConceptScore W2947247246C2777701055 @default.
- W2947247246 hasConceptScore W2947247246C2780057760 @default.
- W2947247246 hasConceptScore W2947247246C44249647 @default.
- W2947247246 hasConceptScore W2947247246C71924100 @default.
- W2947247246 hasFunder F4320321001 @default.
- W2947247246 hasIssue "1" @default.
- W2947247246 hasLocation W29472472461 @default.
- W2947247246 hasLocation W29472472462 @default.
- W2947247246 hasLocation W29472472463 @default.
- W2947247246 hasLocation W29472472464 @default.
- W2947247246 hasOpenAccess W2947247246 @default.
- W2947247246 hasPrimaryLocation W29472472461 @default.
- W2947247246 hasRelatedWork W2055244776 @default.
- W2947247246 hasRelatedWork W2340130805 @default.
- W2947247246 hasRelatedWork W2348529436 @default.
- W2947247246 hasRelatedWork W2413020017 @default.
- W2947247246 hasRelatedWork W2796582438 @default.
- W2947247246 hasRelatedWork W2894792775 @default.
- W2947247246 hasRelatedWork W2948845624 @default.
- W2947247246 hasRelatedWork W4247922271 @default.
- W2947247246 hasRelatedWork W4255240967 @default.
- W2947247246 hasRelatedWork W4281727781 @default.
- W2947247246 hasVolume "7" @default.
- W2947247246 isParatext "false" @default.
- W2947247246 isRetracted "false" @default.
- W2947247246 magId "2947247246" @default.
- W2947247246 workType "article" @default.